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Purpose: The current study aimed to identify metabolites associated with age-related macular degeneration
(AMD) by performing the largest metabolome association analysis in AMD to date, as well as aiming to determine
the effect of AMD-associated genetic variants on metabolite levels and investigate associations between the
identified metabolites and activity of the complement system, one of the main AMD-associated disease
pathways.
Design: Case-control association analysis of metabolomics data.
Participants: Five European cohorts consisting of 2267 AMD patients and 4266 control participants.
Methods: Metabolomics was performed using a high-throughput proton nuclear magnetic resonance
metabolomics platform, which allows quantification of 146 metabolite measurements and 79 derivative values.
MetabolomeeAMD associations were studied using univariate logistic regression analyses. The effect of 52
AMD-associated genetic variants on the identified metabolites was investigated using linear regression. In
addition, associations between the identified metabolites and activity of the complement pathway (defined by the
C3d-to-C3 ratio) were investigated using linear regression.
Main Outcome Measures: Metabolites associated with AMD.
Results: We identified 60 metabolites that were associated significantly with AMD, including increased levels
of large and extra-large high-density lipoprotein (HDL) subclasses and decreased levels of very low-density li-
poprotein (VLDL), amino acids, and citrate. Of 52 AMD-associated genetic variants, 7 variants were associated
significantly with 34 of the identified metabolites. The strongest associations were identified for genetic variants
located in or near genes involved in lipid metabolism (ABCA1, CETP, APOE, and LIPC) with metabolites belonging
to the large and extra-large HDL subclasses. Also, 57 of 60 metabolites were associated significantly with
complement activation levels, independent of AMD status. Increased large and extra-large HDL levels and
decreased VLDL and amino acid levels were associated with increased complement activation.
Conclusions: Lipoprotein levels were associated with AMD-associated genetic variants, whereas decreased
essential amino acids may point to nutritional deficiencies in AMD. We observed strong associations between the
vast majority of the AMD-associated metabolites and systemic complement activation levels, independent of
AMD status. This may indicate biological interactions between the main AMD disease pathways and suggests
that multiple pathways may need to be targeted simultaneously for successful treatment of
AMD. Ophthalmology 2020;127:1693-1709 ª 2020 by the American Academy of Ophthalmology. This is an open
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Ophthalmology Volume 127, Number 12, December 2020Age-related macular degeneration (AMD) is a multifactorial
disease caused by a combination of genetic and environ-
mental factors.1e4 AMD has a strong genetic component,
explaining up to 70% of the variance in disease risk, but
lifestyle habits such as smoking and diet also influence
AMD risk.5e7 The largest genome-wide association study
(GWAS) to date identified 52 genetic variants at 34 loci that
are associated significantly with AMD.2 These variants were
calculated to account for 27.2% of AMD variability, thus
explaining more than half of the genomic heritability
(estimated to be 46.7% in the same study). Genes at these
AMD loci group into 3 main biological pathways: the
complement system, lipid metabolism, and extracellular
matrix remodeling.2 An important role of the complement
system in AMD has also been established by proteomics
studies, which identified components of the complement
system in drusen.8,9 In addition, systemic measurements of
complement activation products, such as C3a, C3d,
and C5a, have consistently been found to be elevated in
AMD.10
Several studies have investigated systemic measurements
of lipid metabolism in AMD, such as dietary fatty acids,
cholesterol, and lipoprotein levels, but results have not al-
ways been consistent among studies.10 A recent meta-
analysis of more than 30 000 individuals from 14 cohorts
investigated the association of cholesterol measurements
and AMD risk.4 Elevated high-density lipoprotein (HDL)
cholesterol levels were identified in AMD, which is opposite
to the effect that has been established in cardiovascular
diseases.11 It has been postulated that size and composition
of lipoprotein particles may be more reliable biomarkers of
cardiovascular disease as compared with general cholesterol
level measurements.12 An exploratory analysis of
lipoprotein subfractions in the Rotterdam Study (RS)
identified increased extra-large HDL to be associated with
AMD.4 A more in-depth analysis of lipoprotein subfractions
using larger sample sizes is needed to further delineate the
associations of lipoprotein particle size and composition in
AMD.
High-throughput systemic measurements of lipids and
other metabolites (metabolomics) can aid in delineating
biomarkers and pathways that contribute to disease patho-
physiologic characteristics. To date, only a small number of
metabolomics studies have been performed in AMD, with
limited sample sizes.13e19 Associations with glycer-
ophospholipids and amino acids have been identified in
some of these studies but results of the studies are difficult to
compare because of different study designs and metab-
olomics approaches.13e20
In the current study, we aimed to perform the largest
metabolomics study in AMD to date using data
collected from 2307 AMD patients and 4294 control
individuals from 5 cohorts. In addition, we aimed to
determine the effect of AMD-associated genetic variants
on metabolite levels and investigate associations be-
tween the identified metabolites and activity of the
complement system, one of the main AMD-associated
disease pathways.1694Methods
Study Populations
Five cohorts were included in this study: the European Genetic
Database (EUGENDA), consisting of 1780 participants at the
Radboud University Medical Center in Nijmegen, The
Netherlands (EUGENDA-Nijmegen); 1534 participants at the
University of Cologne, Cologne, Germany (EUGENDA-Co-
logne)21; the Antioxydants, Lipides Essentiels, Nutrition et
Maladies Oculaires (ALIENOR) study visit 2, consisting of 537
participants from Three-City Study, France3,22; the Münster Age
and Retina Study (MARS) visit 3, consisting of 482 participants
from Münster, Germany23,24; 2640 participants from the RS visit
425,26; and 76 participants from the Combined Ophthalmic
Research Rotterdam Biobank (CORRBI) collected in Rotterdam,
The Netherlands. All cohorts were from similar populations of
European ancestry. The samples from the ALIENOR cohort
were fasting at the time of blood sample collection, whereas the
samples of the other cohorts were collected in a nonfasting state.
All EDTA plasma and serum samples were collected and
centrifuged according to standard protocols and frozen at e80
C within 1 hour.
Only individuals 50 years of age or older were included in the
analysis (Table S1, available at www.aaojournal.org). Individuals
with any stage of AMD were defined as patients, and individuals
without AMD were defined as control participants. Neither the
patients nor the control participants were selected because of the
presence or absence of other diseases. AMD classification was
done separately within each cohort using international
classification systems (File S1, available at www.aaojournal.org).
More detailed descriptions of the cohorts, data collection, AMD
classification, and sampling procedures are provided in
Supplemental File 1 and the references provided in this file.
All studies were approved by the appropriate ethical commit-
tees (Commissie Mensgebonden Onderzoek [CMO] Arnhem-Nij-
megen for EUGENDA-Nijmegen, Ethics Commission of Cologne
University’s Faculty of Medicine for EUGENDA-Cologne, Med-
ical Ethics Committee of the Erasmus Medical Center for RS and
CORRBI, Ethical Committee of Bordeaux for ALIENOR, and
Ethics Committee of the Muenster University Hospital for MARS
cohort), and all participants provided written informed consent.
The study was performed in accordance with the tenets of the
Declaration of Helsinki (7th revision).
Metabolomics Measurements
For EUGENDA, ALIENOR, and RS, EDTA plasma samples were
available, whereas serum samples were available for MARS. For
CORRBI, both plasma and serum samples were available. All
samples were analyzed with a high-throughput proton nuclear
magnetic resonance (NMR) metabolomics platform (Nightingale
Health, Ltd, Helsinki, Finland). This platform provides a total of
225 measurements, which includes ratios and percentages. To
maximize the number of unique measurements in this study, we
removed the markers that were mentioned as ratio or percentage on
the biomarker list of the platform itself (blood biomarker list
located at: https://nightingalehealth.com/biomarkers; accessed
March 27, 2020). This resulted in inclusion of 146 metabolite
measurements in plasma and 3 additional metabolites in serum.
Metabolites measured on this platform include amino acids,
glycolysis measures, ketone bodies, inflammation-related
measurements, fatty acids, and lipoprotein subclasses. Details on
the platform and procedures used for quantification of metabolites
Acar et al  Metabolomics in AMDwere described previously.27 Abbreviations and group names of
the metabolites can be found in Table S2 (available at
www.aaojournal.org). Samples from the EUGENDA-Nijmegen,
EUGENDA-Cologne, ALIENOR, MARS, and CORRBI
cohorts were shipped and measured at Nightingale Health in 1
batch (Nightingale version 2016). Samples from the RS
cohort were shipped and measured previously (Nightingale version
2014).
Quality Control
Principal component analysis was performed on the metabolite
data shared between cohorts to explore potential systematic
deviations between the cohorts.28 Because the CORRBI cohort
included metabolite measurements in both serum and EDTA
plasma samples for the same patients, deviations of principal
components were checked between 2 different sample types.
Thereafter, quality control steps were applied to each cohort
separately. The EUGENDA cohort was analyzed as 2
independent cohorts based on site of inclusion of participants
(i.e., EUGENDA-Nijmegen and EUGENDA-Cologne). For the
CORRBI cohort, the results based on the plasma samples were
selected for further analysis. Quality control consisted of: (1)
exclusion of outliers of metabolite measurements, defined as values
that differed more than 5 times the standard deviation (SD) from
the mean, which were set as missing values; (2) exclusion of
samples with more than 10% missing metabolite measurements;
and (3) exclusion of metabolite measurements with more than 10%
missing values. Finally, we performed a log transformation of each
metabolite measurement. To enable log transformation of 0 values,
1 was added to each measurement. Transformed metabolite values
were standardized, resulting in a standard deviation of 1 and mean
value of 0.
After the quality control procedures were performed, several
different association analyses were performed on the cleaned data.
These models are summarized in Figure S1 (available at
www.aaojournal.org).
Metabolite Association Analysis
MetaboliteeAMD associations were studied using univariate
logistic regression analyses. For each cohort, age, gender, body
mass index, and lipid medication data were available and evaluated
as potential confounders. Selection of confounders was based on
comparison of effect estimates of unadjusted and adjusted regres-
sion models in beb plots (Fig S2, available at
www.aaojournal.org). This resulted in adjustment for age and
gender in all cohorts and additional adjustment for lipid-lowering
medication in the RS cohort. The resulting odds ratios (OR) of
the logistic regression models express the change in odds for AMD
per 1-standard deviation increase of each log-transformed þ1
metabolite level.
Cohort-specific metabolome association analysis results were
combined in a random effects meta-analysis using the R package
‘meta’ (R Foundation for Statistical Computing, Vienna,
Austria).29 A random effects model was chosen to account for
possible heterogeneity resulting from differences in AMD
assessment, AMD severity, and sample collection among cohorts.
Metabolite measurements that were available in only 1 or 2
cohorts after quality control were not meta-analyzed. Heterogene-
ity in the meta-analysis was assessed using the I2 value. Correction
for multiple testing was performed by applying the Benjamini-
Hochberg procedure, a false discovery rate (FDR) correction,
because of the strong correlations between the measured metabo-
lites.20,30 The threshold for statistical significance was defined asan FDR-corrected P value (PFDR) of less than 0.05 after FDR
correction.Association Analysis of Age-Related Macular
Degeneration-Associated Genetic Variants with
Metabolites
For the identified AMD-associated metabolites, a single nucleo-
tide polymorphism (SNP)emetabolite association analysis was
performed to investigate the effect of 52 AMD-associated genetic
variants, reported in the most recent GWAS by Fritsche et al2 on
metabolite levels. Two of our cohorts (EUGENDA-Nijmegen and
EUGENDA-Cologne) were used partially in the study of Fritsche
et al. First, the associations of the 52 genetic variants with AMD
as presented in primary analyses of Fritsche et al were replicated
using data from the 5 cohorts of the current study. Next, the 52
AMD-associated genetic variants were tested in linear regression
models for association with the quality-controlled, log-trans-
formed, and standardized metabolite levels that were found to be
associated significantly with AMD in the metabolomics analysis.
Genetic variants were coded according to an additive model, that
is, as 0 if the patient was homozygous for the reference allele, as
1 if the patient was heterozygous, carrying 1 copy of each allele,
and as 2 if the patient was homozygous for the alternative allele.
For the genetic variants that were not genotyped directly, that is,
variants that were not present on the genotyping platforms that
were used to measure genotypes in the cohorts, we used statis-
tical imputation with Haplotype Reference Consortium and 1000
Genomes as a reference panel to estimate genotypes for all
nondirectly genotyped variants.31,32 Quality control of the
genetic data and imputation can be found in the publications of
each cohort (Colijn et al, unpublished data, 2020; de Breuk
et al33 2020.2,34e36 For the imputed variants, dosage informa-
tion was used as genotype to take the uncertainty in genotype
imputation into account. Per cohort, the percentage of imputed
variants of the 52 genetic variants were: EUGENDA-Nijmegen,
9%; EUGENDA-Cologne, 11%; ALIENOR, 22%; and RS,
23% of the total genotypes within the cohorts. All of the avail-
able genetic data of CORRBI were genotyped directly, so none of
the 52 genetic variants had to be imputed. Reference and alter-
native alleles were defined as presented in the AMD GWAS of
Fritsche et al.2 For the cohorts with multiple sequencing platform
data, the inclusion preference from high to low was single-
molecule molecular inversion probes sequencing, whole-exome
sequencing, exome chip direct genotyping, and exome chip
imputed genotypes (Colijn et al, unpublished data, 2020). AMD
status was used as a covariate in the regression models to account
for the potential confounding effect of disease status, along with
age and gender. Cohort-specific results were combined in a fixed-
effects meta-analysis because the underlying effect of the genetic
variants on the metabolites was assumed to be the same in each
cohort. The threshold for statistical significance was again
defined as PFDR < 0.05 after FDR correction.
To identify whether the metabolites are acting as mediators of
the association between genetic variants and AMD, for example, if
lipoprotein levels can explain the association between a genetic
variant and AMD, a mediation analysis was performed by building
2 regression models for each associated metabolite and genetic
variant. The first model (model A) was a linear regression model
with the AMD-associated genetic variant as predictor of the
associated metabolite measurement. The second model (model B)
was a logistic regression model with the AMD-associated genetic
variant and the associated metabolite predicting AMD status. These
models were also adjusted for age and gender. Based on these
model duos (models A and B), we calculated the average casual1695
Ophthalmology Volume 127, Number 12, December 2020mediation effects (ACMEs) for each SNPemetabolite duo in each
cohort using the “mediate” function of the R package “Mediation.”
Resulting cohort-specific ACMEs were subsequently meta-
analyzed to combine the results across cohorts.
Additionally, we tested whether the genetic varianteAMD
associations were mediated by a combination of metabolites
instead of only 1, thereby focusing only on those metabolites that
showed a statistically significant association with the genetic
variant under study. For this, we built a logistic regression model
with the genetic variant as predictor, AMD as outcome, and all
genetic variant-associated metabolites as covariates (model C).
This was carried out for each cohort separately, except for
CORRBI cohort because of its low sample number, which was not
sufficient to include all associated metabolites in the model for
some of the genetic variants. The results were combined in a
random effects meta-analysis. We compared effect estimates and P
values of model C with single variant association models, that is,
with the genetic variant as the predictor and AMD status as the
outcome.
Association Analysis of Complement Activation
with Metabolites
For the identified AMD-associated metabolites, we studied the
association between metabolites and activity of the complement
pathway. For the EUGENDA cohort, systemic complement acti-
vation measurements (defined by the C3d-to-C3 ratio) were
available for a total of 3073 individuals because they were used
previously to test the effect of genetic variants on complement
activation.37,38 For the metaboliteecomplement activation associ-
ation analyses, we analyzed the EUGENDA cohort as 2 indepen-
dent cohorts based on site of inclusion of participants (i.e.,
EUGENDA-Nijmegen and EUGENDA-Cologne). After log
transformation and standardization of the complement activation
levels for these 2 cohorts, a linear regression model was built. In
this model, significantly associated metabolites were tested 1 by 1
as independent variables; systemic complement activation was
used as a dependent variable; and age, gender, and AMD status
were used as covariates. Results from the 2 cohorts were combined
in a random effects meta-analysis to investigate the associations
between complement activation and significant metabolites. False
discovery rate correction for multiple testing was applied because
of the strong correlations between the metabolites and a signifi-
cance threshold of PFDR < 0.05. The same linear regression models
were also built for AMD patients and healthy control participants
separately to compare the effect estimates between patients and
control participants.Results
Study Population and Quality Control
Metabolomics measurements were performed in 7049 plasma and
serum samples from 5 cohorts using a high-throughput proton
NMR metabolomics platform, which allows the quantification of
146 metabolite measurements in EDTA plasma (Table S2). The
maximum number of outliers per metabolite was 13 for
EUGENDA-Nijmegen, 9 for EUGENDA-Cologne, 5 for
ALIENOR, 1 for CORRBI, and 49 for RS. The number of samples
filtered out because of 10% missingness was 11 for EUGENDA-
Nijmegen, 6 for EUGENDA-Cologne, 2 for ALIENOR, 0 for
CORRBI, and 15 for RS. Measurement level check for 10%
missingness resulted in removal of valine in the CORRBI cohort
and 3-hydroxybutyrate in both the ALIENOR and CORRBI-
plasma cohorts.1696Principal component analysis showed a general cluster formed
by the measurements of all cohorts, but the MARS cohort clustered
outside of this cluster (Fig S3, available at www.aaojournal.org).
This was not the result of the difference between plasma and
serum measurements, because serum samples from CORRBI
clustered along with plasma samples from CORBBI and all other
cohorts. Rather, it may indicate a potential difference in quality
of the samples.28 Additionally, we received a quality report of
the Nightingale platform measurements mentioning that higher
than normal pyruvate and lactate levels were observed for the
MARS cohort, indicating that the MARS samples may have
been kept at room temperature for too long.39 To prevent
inclusion of low-quality samples in our study, we excluded the
MARS cohort from further analysis. Because of exclusion of the
MARS cohort, which was the only cohort with only serum samples
available, all metabolites included in our study are based on
measurements in plasma samples.
After cohort-specific quality control, 146 metabolites
(Table S2) and a total of 6533 samples of 2267 AMD patients and
4266 control participants (Table 1) remained for further analysis.
The average age of all of the participants in this study was 74
years, and 58% of the remaining participants were women. More
detailed information about age, gender, and lipid-altering medica-
tion use in the remaining samples can be found in Table S1.
Metabolite Associations with Age-Related
Macular Degeneration
Meta-analyses identified 60 metabolite measurements that were
associated significantly with AMD (PFDR < 0.05; Fig 1; Table S3,
available at www.aaojournal.org), which showed high correlations
among lipid-related metabolites (Fig S4, available at
www.aaojournal.org). For the lipoprotein subclasses, significant
associations in particular were observed in the very low-density
lipoprotein (VLDL) and HDL subclasses. Significantly associated
metabolite measurements also included 3 other lipid and
apolipoprotein measurements, 3 fatty acids, 1 glycolysis-related
metabolite, and 5 amino acids.
Of the 42 VLDL-related subclass measurements, 30 were
associated inversely with AMD (OR, <1), indicating that AMD
patients have decreased VLDL levels compared with control par-
ticipants. Measurements of all VLDL subclasses were associated
with AMD, except for very small VLDL. The most significant
association was observed for cholesterol esters in medium
VLDL (OR, 0.89; 95% CI, 0.84e0.95; PFDR ¼ 0.014; Fig 2). Of
28 HDL-related subclass measurements, 5 very large and 6 large
HDL measurements were associated positively with AMD (OR,
>1), indicating that AMD patients have increased very large and
large HDL levels compared with control participants. The most
significant association was observed for phospholipids in very
large HDL particles (OR, 1.12; 95% CI, 1.05e1.20; PFDR ¼ 0.014;
Fig 2). Only 1 medium HDL measurement was associated
significantly with AMD, whereas none of the 7 small HDL
measurements were associated with AMD. None of the 7
intermediate-density lipoprotein-related and 21 of the LDL-
related subclass measurements were associated significantly with
AMD (Fig 1).
Of other lipid and apolipoprotein measurements, decreased
remnant cholesterol level (remnant-C; OR, 0.90; 95% CI,
0.85e0.96; PFDR ¼ 0.017), apolipoprotein B (ApoB; OR, 0.91:
95% CI, 0.86e0.97; PFDR ¼ 0.022), and total serum triglycerides
(OR, 0.91; 95% CI, 0.86e0.97; PFDR ¼ 0.020) were identified in
AMD patients compared with control participants (Fig 2). In
addition, 3 fatty acids were associated significantly with AMD
(Fig 3). Decreased levels of monounsaturated fatty acids
(MUFAs), saturated fatty acids (SFA), and total fatty acids
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385 (72) 785 (45) 903 (59) 31 (41) 2162 (82) 4266 (65)
*Remaining number of samples after quality control is shown. In our analysis, we used any stage of age-related macular degeneration (AMD) as patients and
non-AMD individuals as control participants. All samples were from European ancestry.
Acar et al  Metabolomics in AMD(TotFA) were identified in AMD patients compared with control
participants, with effect estimates ranging from an OR of 0.92 to
0.93 (95% CI, 0.86e0.98; PFDR ¼ 0.005e0.014).
Of 3 glycolysis-related metabolites, a decreased citrate level
was identified in AMD patients compared with control participants
(OR, 0.88; 95% CI, 0.83e0.94; PFDR ¼ 0.010; Fig 4). In addition,
decreased levels of 5 amino acids were identified in AMD (Fig 4).
The most significant association was observed for phenylalanine
(OR, 0.86; 95% CI, 0.81e0.91; PFDR ¼ 1.54  10e4), which
was highly consistent among the cohorts (I2 ¼ 0). Levels of
alanine, isoleucine, leucine, and tyrosine were also decreased
significantly in AMD patients compared with control
participants, although these measurements showed moderate
heterogeneity between the cohorts (I2 ¼ 0.5e0.6; Fig 4). No
significant associations with AMD were observed for metabolites
related to fluid balance (albumin, creatinine), ketone bodies
(acetate, acetoacetate, 3-hydroxybutyrate), and inflammation
(glycoprotein acetyls; Fig 1).
Associations of Age-Related Macular
Degeneration-Associated Genetic Variants with
Metabolites
Associations of 52 AMD-associated genetic variants with AMD
and comparison with the results as presented by Fritsche et al2 are
shown in Table S4 (available at www.aaojournal.org). The
directions of effects for 50 variants were validated to be similar
between our study and that of Fritsche et al. For 2 SNPs,
rs2043085 in the LIPC gene and rs10033900 in the CFI gene,
we observed an opposite direction of effect, but both associations
were not statistically significant.
For the 60 identified AMD-associated metabolites, a
geneemetabolite association analysis was performed to investigate
the association of 52 AMD-associated genetic variants, reported in
the most recent GWAS by Fritsche et al,2 with metabolite levels.
We identified 98 significant associations, comprising 34
metabolite measurements and 7 SNPs (Fig 5; Table S5, available
at www.aaojournal.org). Six of these SNPs are located in or near
genes involved in lipid metabolism (ABCA1, CETP, APOE, and
LIPC). The seventh SNP (rs10781182) resides in the MIR6130
gene, which encodes a microRNA. The largest number of
SNPemetabolite associations were identified in the metabolitesbelonging to the large and very large HDL subclasses, with a total
of 50 associations between different subclasses and variants.
The T allele of rs17231506 in the CETP gene, which is asso-
ciated with an increased risk of AMD, showed the largest number
of significant associations (26 in total). The T allele of rs17231506
was associated with increased levels of 13 HDL-related measure-
ments (b > 0) and decreased levels of 11 VLDL-related mea-
surements (b < 0). Among these associations, free cholesterol in
very large HDL was the most significant association
(PFDR ¼ 1.57  10e24; b for allele T, 0.20; 95% CI, 0.17e0.24) of
all geneemetabolite associations. A second independent variant in
the CETP gene, rs5817082, of which the CA allele (A insertion) is
associated with decreased AMD risk, showed 22 significant asso-
ciations with similar metabolites as rs17231506, albeit with an
opposite direction of effect. The CA allele of rs5817082 was
associated with decreased levels of 13 HDL-related measurements
(b < 0) and increased levels of 8 VLDL-related measurements
(b > 0).
Variant rs2043085 in the LIPC gene, of which the C allele is
associated with an increased risk of AMD (Table S4),2,40 showed
21 significant associations. The C allele of rs2043085 was
associated with decreased levels of 15 HDL-related measure-
ments (b < 0), decreased levels of 2 small VLDL-related
measurements (b < 0), and decreased levels of 3 fatty acids
measurements: MUFA, SFA, and TotFA (b < 0). A second
independent variant in the LIPC gene, rs2070895, of which the A
allele is associated with a decreased risk of AMD, showed 18
significant associations with similar metabolites as rs2043085,
albeit with an opposite direction of effect. The A allele of
rs2070895 was associated with increased levels of 14 HDL-related
measurements (b > 0), decreased levels of 2 VLDL-related
measurements (b < 0), and increased levels of 2 fatty acid
measurements, SFA and TotFA (b > 0).
Variant rs429358 in the APOE gene, of which the C allele is
associated with a decreased risk of AMD, showed 5 significant
associations with metabolite levels. The C allele of rs429358 was
associated with increased levels (b > 0) of ApoB, remnant-C, a
small VLDL measurement, and cholesterols in very large HDLs,
whereas an opposing effect was observed for triglycerides in a
medium HDL measurement. Variant rs2740488 in the ABCA1
gene, of which the C allele is associated with a decreased risk of
AMD, was associated with decreased levels of 5 HDL-related1697
Figure 1. Metabolites associated with age-related macular degeneration (AMD). Effect sizes (odds ratios [ORs]) are indicated with bars, and the black circle
indicates the no-effect level (OR, 1). Bars pointing outward of the black circle are associated with increased levels in AMD (OR, >1), whereas bars pointing
inward of the black circle are associated with decreased levels in AMD (OR, <1). Colors indicate the false discovery rate-corrected significance level. For
abbreviations of the metabolites, see Table S2.
Ophthalmology Volume 127, Number 12, December 2020measurements (b < 0). Variant rs10781182 in the MIR6130 gene,
of which the T allele is associated with an increased risk of AMD,
showed a significant association with citrate (PFDR ¼ 4.52  10e2;
b for allele T, e0.06; 95% CI, e0.10 to 0.02; I2 ¼ 0).
Next, a mediation analysis was performed to examine if the
association of the genetics variants with AMD can be explained
(i.e., are mediated) by the associated metabolites. Two different
approaches were adopted for this. First, each metabolite was
evaluated individually for a mediation effect by estimating the
ACMEs in every cohort. Meta-analyzed ACMEs revealed no
significant mediation effect of any of the metabolites for the
SNPeAMD associations (Table S6, available at
www.aaojournal.org). Second, all metabolites that were found to
be associated with a genetic variant were evaluated jointly for a
mediation effect by comparing the effect estimates of the genetic1698variant on AMD in an unadjusted and metabolite-adjusted model.
In case of (partial) mediation, effect estimates will be lower in the
adjusted model. However, we observed that effect estimates were
increased rather than decreased (Table S7, available at
www.aaojournal.org). Consistent with the first analysis using
quantified metabolites, this second analysis thus also revealed no
mediation effect.
Associations of Complement Activation with
Metabolites
Because the complement pathway is one of the main disease
pathways in AMD pathogenesis, we next investigated associations
between AMD-associated metabolites and activity of the comple-
ment system measured as the C3d-to-C3 ratio. The analysis
Figure 2. Forest plots showing the most significantly associated very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) subparticles,
remnant cholesterol level (remnant-C), apolipoprotein B (ApoB), and triglycerides with age-related macular degeneration (AMD). The effect estimate (EE)
shows the b effect estimate, and the 95% confidence interval (CI) shows the 95% CI of this effect estimate. Random effects meta-analysis estimation is
shown in the figures. ALIENOR ¼ Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires; CORRBI ¼ Combined Ophthalmic Research
Rotterdam Biobank; EUGENDA ¼ European Genetic Database; M-VLDL-CE ¼ cholesterol esters in medium VLDL; serum-TG ¼ serum total triglycerides;
XL-HDL-PL ¼ phospholipids in very large HDL.
Acar et al  Metabolomics in AMD
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Figure 3. Forest plots showing significantly associated fatty acids. The effect estimate (EE) shows the b effect estimate, and the 95% confidence interval (CI)
shows the 95% CI of this effect estimate. Random effects meta-analysis estimation is shown in the figures. ALIENOR ¼ Antioxydants, Lipides Essentiels,
Nutrition et Maladies Oculaires; CORRBI ¼ Combined Ophthalmic Research Rotterdam Biobank; EUGENDA ¼ European Genetic Database;
MUFA ¼ monounsaturated fatty acids (oleic and palmitoleic); SFA ¼ saturated fatty acids; TotFA ¼ total fatty acids.
Ophthalmology Volume 127, Number 12, December 2020was performed on AMD patients and control participants of
the EUGENDA cohorts and was adjusted for AMD status. Of 60
significantly associated metabolite measurements, 57 were found
to be associated significantly with complement activation
(Table S8, available at www.aaojournal.org). Effect estimates of
significant associations were similar for AMD patients and
control participants when stratifying instead of adjusting for
AMD status.1700For all AMD-associated VLDL measurements, decreased
VLDL levels were associated with increased complement activity
(b < 0). Conversely, increased levels of all large and very large
HDL subclasses showed a significant association with increased
levels of C3d or C3 (b > 0). For other lipid and apolipoprotein
measurements, decreased remnant-C, ApoB, and total serum tri-
glycerides were associated with increased complement activation
(b < 0). In addition, of the AMD-associated fatty acid
Figure 4. Forest plots showing significantly associated amino acids and citrate. The effect estimate (EE) shows the b effect estimate, and the 95% confidence
interval (CI) shows the 95% CI of this effect estimate. Random effects meta-analysis estimation is shown in the figures. Ala ¼ alanine;
ALIENOR ¼ Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires; Cit ¼ citrate; CORRBI ¼ Combined Ophthalmic Research Rotterdam
Biobank; EUGENDA ¼ European Genetic Database; Ile ¼ isoleucine; Leu ¼ leucine; Phe ¼ phenylalanine; Tyr ¼ tyrosine.
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Ophthalmology Volume 127, Number 12, December 2020measurements, decreased MUFA, SFA, and TotFA levels were
associated with increased complement activation (b < 0).
Of 5 amino acids that were associated with AMD status,
decreased levels of alanine, isoleucine, and leucine were associated
significantly with increased complement activation levels (b < 0).
These 3 amino acids showed less significance in terms of associ-
ation compared with the associations of the other metabolites, and
the associations were heterogeneous among the cohorts
(I2 ¼ 0.54e0.74). Phenylalanine, tyrosine, and citrate were not
associated significantly with complement activation levels.Discussion
In the current study, we performed the largest metabolomics
analysis in AMD to date, including 2307 AMD patients
and 4294 control individuals from 5 cohorts. Using an
NMR-based platform, 146 metabolite measurements were
quantified in plasma. Overall, we identified 60 metabolite
measurements that were associated significantly with AMD.
Among the significant associations were HDL and VLDL
lipoprotein particles, other lipids and apolipoproteins
(remnant C, ApoB, serum triglycerides), fatty acids (MUFA,
SFA, and TotFA), amino acids (alanine, isoleucine, leucine,
phenylalanine, and tyrosine), and citrate (Fig 6A). Several
lipid-related metabolites were correlated highly with each
other (Fig S4, available at www.aaojournal.org).
High-density lipoprotein levels were increased in AMD,
whereas VLDL levels were decreased in AMD. These
findings are in agreement with previous findings, because
increased HDL levels were also recently reported for AMD
in a large meta-analysis of 30 000 individuals from Euro-
pean cohorts.4 Our current study showed that particle size
and composition of lipoproteins are relevant: associations
were identified with very large and large HDL but not
with medium and small HDL. For VLDL, we identified
associations with all subparticles except for very small
VLDL, whereas medium VLDL was most significant. In
dementia, increased large HDL levels have also been
associated with an increased risk, whereas small VLDL
levels are associated with a decreased risk of dementia.41
Intriguingly, the associations in AMD and dementia are
opposite to what is observed in cardiovascular disease
(CVD). Increased HDL levels are associated with a
decreased risk of CVD, whereas increased VLDL levels
are associated with an increased risk of CVD.11,42
Lipoprotein associations in CVD extend to all VLDL,
intermediate-density lipoprotein, LDL, and HDL sub-
particles, although the strongest effect is observed for large
HDL.43 The different associations among lipoprotein
subparticle sizes support the notion that the composition
of lipoproteins may be important, and this can affect their
functional role.44 Further research into the composition of
HDL and VLDL subparticles among different diseases is
warranted to understand the meaning of these associations.12
Decreased MUFA, SFA, and TotFA levels were identi-
fied in AMD patients compared with control participants in
the current metabolomics study. Conversely, increased
MUFA and SFA have been associated with an increased risk
of CVD.43 Previous epidemiologic studies found
inconsistent associations of MUFA and SFA with AMD,1702and many results were not statistically significant.12
Among MUFAs, oleic acid, a main constituent of olive
oil, may have a protective effect on AMD, whereas other
MUFAs may exert a detrimental effect.45 Therefore, more
detailed analyses of specific fatty acids are needed to
determine their effect on AMD risk. The NMR-based plat-
form used in this study does not perform such a detailed
analysis; moreover, fatty acid measurements in red blood
cell membranes may reflect longer-term dietary intakes than
plasma measurements, which are subject to daily
variations.46
We detected decreased amino acid (alanine, isoleucine,
leucine, phenylalanine, and tyrosine) and citrate levels in
AMD patients compared with control participants. A recent
metabolomics study in urine samples also showed depleted
citrate and amino acid levels in AMD, which was suggested
to reflect an enhancement in energy requirement in the
disease.47 Decreased amino acid levels (valine, isoleucine,
leucine) have also been reported in dementia.41 Valine,
isoleucine, leucine, and phenylalanine are essential amino
acids, and circulating levels are determined largely by
dietary intake.48 Thus, reduced levels of these essential
amino acids may indicate subclinical nutritional
deficiencies in dementia and AMD. In addition, branched
amino acids (valine, isoleucine, leucine) are associated
with muscle mass,49 which may reflect reduced physical
activity in dementia and AMD. Moreover, studies have
reported that certain bacteria of the gut microbiome can
covert phenylalanine and tyrosine to other derivative
metabolites, possibly leading to reduced uptake and
consequently reduced plasma levels of these amino
acids.50,51 Future studies on the role of the gut
microbiome in AMD would therefore be of interest.
Notably, the same 5 amino acids (alanine, isoleucine,
leucine, phenylalanine, and tyrosine) that were associated
with AMD in our study were found to be increased in
CVD, suggesting that not only lipoproteins and fatty acids
but also amino acid metabolism exert opposite effects in
AMD and CVD.43 Inverse associations have also been
reported for genetic risk for AMD as opposed to CVD:
individuals with increased genetic risk for CVD and
related traits have a lower genetic risk for AMD.40
Therefore, pleiotropic effects seem to underlie AMD and
CVD, reflected by opposite effects of genetic risk as well
as metabolite measurements. Notably, some epidemiologic
studies have suggested CVD as a potential risk factor for
AMD, but conflicting results have been reported among
studies. A large meta-analysis showed that the associations
between AMD and CVD remain inconclusive.52
Identification of altered metabolite levels in plasma
points toward systemic effects in AMD and suggests that the
identified metabolites represent promising biomarkers for
AMD. Analysis of the identified metabolites in prospective
cohorts over time is recommended to determine their value
as early predictors of AMD or biomarkers for disease pro-
gression. Such follow-up studies will need to explore
whether a combined group of metabolites has added value to
predict disease progression before such biomarkers can be
implemented into clinical practice. Epidemiologic and
intervention studies have reported that nutritional and
Figure 5. Dot plot showing associations between metabolites and age-related macular degeneration (AMD)-associated genetic variants. This plot shows the
association results of AMD-associated single nucleotide polymorphisms, as defined by Fritsche et al,2 with the metabolite levels that were significant
associated with AMD in our meta-analysis. The y-axis shows log-transformed false discovery rate-corrected P values (elog(PFDR)). HDL ¼ high-density
lipoprotein; L ¼ large; M ¼ medium; S ¼ small; VLDL ¼ very low-density lipoprotein; XL ¼ very large; XXL ¼ very very large.
Acar et al  Metabolomics in AMDlifestyle factors contribute to the development of AMD, and
several nutrients such as lutein, zeaxanthin, vitamins C and
E, zinc, and fatty acids may help to reduce the risk of
AMD.12 Our study suggested that investigation into the
effect of dietary interventions in AMD may be extended
to other nutrients, such as essential amino acids, although
we cannot exclude that these associations may be related
to reduced physical activity or an altered gut microbiome
rather than reduced dietary intake.
Most AMD-associated metabolites identified in this
study are influenced by both environmental and genetic
factors, but the relative contribution differs between me-
tabolites. Although the identified amino acids to a large
extent are driven by environmental factors, HDL levels have
a strong genetic component (heritability is estimated to be
70%).48 In the current study, we investigated the association
of 52 AMD-associated genetic variants with metabolitelevels. Associations were detected with variants in the
CETP, LIPC, ABCA1, and APOE genes, encoding compo-
nents of the HDL metabolism pathway: cholesteryl ester
transfer protein; lipase C, hepatic type; adenosine
triphosphate-binding cassette transporter A1; and apolipo-
protein E. Cholesteryl ester transfer protein exchanges
cholesteryl esters and triglycerides between HDL and other
lipoproteins and thereby influences HDL particle size.
Lipase C, hepatic type, hydrolyses triglycerides and
phospholipids in lipoproteins, partly converts very large
VLDL and intermediate-density lipoprotein to LDL and
plays a role in altering the HDL content. Adenosine
triphosphate-binding cassette transporter A1 forms a cellular
cholesterol efflux pump leading to formation of nascent
HDL. Apolipoprotein E facilitates cholesterol uptake by
HDL.4 Most of the AMD-associated variants in the CETP,
LIPC, ABCA1, and APOE genes are intronic or intergenic,1703
Figure 6. Overview of metabolomics, genetic variants, and complement activation in age-related macular degeneration (AMD). A, Diagram showing an
increase in metabolite levels or AMD risk with red lines and a decrease in metabolite levels or AMD risk with green lines, according to the effect estimates.
Environmental factors are known to affect metabolites,48 AMD, and complement activation,38 depicted with gray lines. Black lines show associations with
different directions of effect, which are shown in more detail in (B). B, Table in which, for each genetic variant that was associated with a lipoprotein
subparticle and fatty acid measurement in their related metabolite groups, effects are shown as plus for effect estimate of more than 0 and minus for
effect estimate of less than 0. In cases where there were no associations with the group, it is shown as 0 in the table. The number of plus or minus signs
indicates the significance of the P value, where 0.05  P > 0.001 is shown as þ or e, 0.001  P > 0.0001 is shown as þþ or e e, and 0.0001  P
is shown as þþþ or e e e. AMD ¼ age-related macular degeneration; HDL ¼ high-density lipoprotein; L ¼ large; MUFA ¼ monounsaturated fatty
acid; SFA ¼ saturated fatty acid; TotFA ¼ total fatty acid; VLDL ¼ very low-density lipoprotein; XL ¼ very large.
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Acar et al  Metabolomics in AMDand the functional effects of these variants are not clear, with
the exception of the rs429358 variant (APOE e4 allele) in
APOE leading to the amino acid change Cys156Arg, which
alters the lipoprotein binding properties of APOE.12 In our
analysis, the strongest effect estimates were detected for
large and very large HDL levels, which were mainly
associated with variants in the CETP (rs17231506,
rs5817082) and LIPC (rs2043085, rs2070895) genes, and
weaker associations were identified in the ABCA1
(rs2740488) and APOE (rs429358) genes. Genetic variants
in CETP, LIPC, and APOE were also associated with
VLDL, although these associations were weaker than
those observed for large and very large HDL. Fatty acids
(MUFA, SFA, and TotFA) were associated with variants
in LIPC, but no associations were detected with variants
in CETP, ABCA1, and APOE. For most SNPeHDL asso-
ciations, we observed the expected direction of effect, where
AMD risk-conferring alleles were associated with increased
large and very large HDL levels, whereas protective AMD
alleles were associated with decreased HDL levels (Fig 6B).
The exceptions are the variants in the LIPC gene. The C
allele of LIPC variant rs2043085 is associated with an
increased risk of AMD, whereas it is associated with
decreased large and very large HDL levels. Similarly, the
A allele of LIPC variant rs2070895 is associated with a
decreased risk of AMD, whereas it is associated with
increased large and very large HDL levels. The inverse
effect of LIPC variants on AMD and HDL levels was also
noted in other studies, which concluded that not all
mechanisms for increased circulating HDL concentration
increase AMD risk uniformly.4,53 A potential explanation
is that the variants may have a local effect on the lipid
metabolism in the retina, and the association with
circulating HDL is the result of the effect on other tissues
that express these genes and are known to regulate
circulating HDL levels, like the liver.12 In the current
study, we performed a mediation analysis to investigate
whether AMD-associated genetic variants exert their effect
on AMD via the identified metabolites. We did not find
evidence for mediation effects, suggesting that the genetic
variants do not influence AMD via the tested metabolites. A
possible explanation is that the genetic variants influence
AMD disease pathways locally, such as the local lipid
metabolism in the retina. This finding suggests that the
systemic metabolites identified in this study represent rele-
vant biomarkers of local processes, but further investigation
is needed to evaluate whether systemic lipids and lipopro-
teins also have a direct effect on the pathophysiologic
characteristics of AMD.
Genetic variants in genes of the complement system are
well-established determinants of AMD risk, with the
strongest associations identified at the complement factor H
(CFH) locus. In this study, we did not observe any associ-
ations of AMD-associated genetic variants in the comple-
ment system with AMD-associated metabolites. It is known
that AMD is associated with increased systemic comple-
ment activation, which in this study was defined as the C3d-
to-C3 ratio.54 Notably, we observed strong associations of
systemic complement activation measurements with
AMD-associated metabolites, including lipoproteinsubfractions (large and very large HDL and VLDL), other
lipids and apolipoproteins (remnant-C, ApoB, and
triglycerides), fatty acids (MUFA, SFA, and TotFA), and
amino acids (leucine, isoleucine, and alanine), and these
associations were independent of AMD status. The direction
of effect of the complementemetabolite associations were
in alignment with the direction of effect of
AMDemetabolite associations. Increased large and very
large HDL levels were associated with increased comple-
ment activation, and both HDL levels and complement
activation were increased in AMD patients compared with
control participants. However, decreased VLDL, remnant-
C, ApoB, triglycerides, MUFA, SFA, TotFA, isoleucine,
leucine, and alanine levels were associated with increased
complement activation, and these metabolites were
decreased in AMD patients compared with control partici-
pants (Fig 6). Although these statistical associations do not
prove causality, they may indicate biological interactions
between the main AMD disease pathways: lipid
metabolism and complement activation. A potential
interaction between HDL and the complement system was
shown in proteomic studies that demonstrated that HDL
lipoprotein particles contain various complement
components.44 Notably, large HDL subparticles were
shown to contain complement factor H (CFH), whereas
small HDL and medium HDL subparticles did not.
Although Zhang et al44 propose that the increased CFH
concentration would provide large HDL subparticles with
anti-inflammatory properties, our study suggested the
opposite: increased large HDL levels were associated with
increased systemic complement activity. Perhaps increased
uptake of CFH by large HDL subparticles leads to reduced
levels of circulating unbound CFH, subsequently causing
increased activity of the complement system. Recent studies
have also shown that dietary intake of fatty acids is asso-
ciated with complement system activity.55,56 The biological
mechanisms of whether and how the AMD-associated me-
tabolites interact with the complement system should be
investigated in future studies. Besides biological studies,
future studies could also apply statistical approaches such as
Mendelian randomization to study causal mechanisms
among metabolites, disease pathways, and AMD.
Our study has several strengths and weaknesses. A
strength of our study is the analysis of metabolite mea-
surements in 6533 samples, which makes it the largest
metabolomics study performed so far in AMD. Most of the
identified metabolite associations were identified consis-
tently among cohorts. The large sample size of our study
allowed a thorough analysis of genetic associations for the
identified metabolites. In addition, the availability of
complement activation measurements for the EUGENDA
cohort enabled us to study associations among the different
AMD disease pathways.
Our study also has some weaknesses. We used an NMR-
based targeted metabolomics platform, and it must be noted
that this platform involves a limited number of measure-
ments compared with mass spectrometry-based approaches.
However, the platform has been used by a large number of
epidemiologic studies, and the measurements provided are
direct quantifications, which are consistent between batches1705
Ophthalmology Volume 127, Number 12, December 2020and studies. Next, AMD classifications slightly differed
among cohorts (Supplemental File 1). To study differences
in metabolite associations among AMD stages,
harmonization of the AMD classifications should be
performed in a follow-up study. We also acknowledge
that systemic (blood) measurements may not reflect the local
disease mechanisms in AMD. The samples from ALIENOR
were fasting samples, whereas the samples of the other
cohorts were collected in a nonfasting state. In Figures 2
through 4 and Table S3, the association results for each
cohort are shown to provide more information on the
effects in fasting samples. Lipid-altering medication was
used as a covariate in the analyses of the RS, whereas no
confounding effect of lipid-lowering medication was
observed in the other cohorts. However, we cannot exclude
that there may be residual confounding because of inaccu-
rate documentation of lipid-altering medication through self-
reported questionnaire data. It must also be noted that
because of being restricted to European samples within our
study, the findings may be different for different ethnical
backgrounds.
In conclusion, we identified 60 metabolites that were
associated with AMD, including HDL and VLDL lipopro-
tein particles, fatty acids (TotFA, MUFA, and SFA), amino
acids (alanine, isoleucine, leucine, phenylalanine, and
tyrosine), and citrate. Strong associations between the vast
majority of the AMD-associated metabolites and comple-
ment activation may indicate biological interactions between
the main AMD pathways, and multiple disease pathways
may need to be targeted for successful treatment of AMD.References
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Anneke.denhollander@radboudumc.nl.Pictures & PerspectivesValsalva Choroidopathy: A Rare Manifestation of Acutely Elevated Venous Pressure
A 27-year old woman who was 10 weeks pregnant presented with an acute central scotoma in her right eye that occurred immediately
following a pregnancy-associated emetic episode. Dilated examination revealed a submacular choroidal hemorrhage without epiretinal
hemorrhage, dehemoglobinized blood at the inferior border of the hemorrhage, and 2 blot retinal hemorrhages along the inferior arcade (Fig
A). OCT showed pigment epithelium elevation with outer retinal hypo- and hyper-reflectivity, ellipsoid zone (EZ) disruption, and choroidal
thickening (Fig B). This is a rare presentation of Valsalva-induced submacular choroidal hemorrhage due to emesis. (Magnified version of
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